Moderna (NASDAQ: MRNA) shares experienced a significant surge on Friday, jumping 12.59% to close at $67.27, a price that now exceeds the average 12-month analyst target of $45.42 by more than 32%. The stock continued its upward momentum in premarket trading Monday, reaching $67.63, up 0.54%. This rally comes as the company prepares for a critical FDA decision on its mRNA-based flu vaccine, with a verdict expected by August 5.
The surge, which drove trading volume to 14.46 million shares—more than double the 65-day average—places Moderna near its 52-week high of $69.29, a stark contrast to its 2024 low of $22.28. The stock has gained 128.11% year-to-date, according to MarketWatch, yet a significant 16.15% of its float remains sold short, indicating lingering bearish sentiment despite the recent rally.
Analyst Targets and Ratings Lag Behind
Despite the sharp rise, Wall Street analysts have been slow to adjust their outlooks. According to Google Finance, among 16 analysts covering Moderna over the past three months, only one rates it a Buy, 13 recommend Hold, and two suggest Sell. The average 12-month price target stands at $45.42, implying a potential 32.48% downside from Friday's close. The highest target, from Piper Sandler's Edward Tenthoff, is $77, offering a 14.46% upside, while the lowest, from an unidentified source, sits at $33, representing a 50.94% decline.
Barclays analyst Eliana Merle reaffirmed a Hold rating with a $48 target on Monday, while Piper Sandler upgraded its stance to Buy and raised its target to $77 on Friday, reflecting a split view among analysts. Goldman Sachs' Salveen Richter also maintains a Hold with a $49 target, suggesting that the recent price move may be overdone relative to near-term fundamentals.
FDA Decision Looms for mRNA Flu Vaccine
The upcoming FDA decision on Moderna's mRNA flu vaccine, mFlusiva, is a key catalyst. On June 18, FDA advisors unanimously agreed that the vaccine's benefits outweigh risks for adults aged 50 and older. If approved, it would mark the first U.S. flu vaccine utilizing mRNA technology. However, Citi analyst Geoff Meacham expects meaningful revenue from mFlusiva to materialize only in the second half of 2027, as Moderna missed the 2026 U.S. flu vaccine contracting window. Jefferies' Andrew Tsai projects $750 million in combined U.S. sales from Moderna's flu shot and COVID-flu combo by 2030, according to Reuters.
Moderna's pipeline extends beyond flu. During its Science Day event, the company emphasized its ambition to be seen as a platform company, not just a vaccine developer. CEO Stéphane Bancel stated that Moderna is building "a platform capable of repeatedly creating new medicines." Key pipeline assets include mRNA-6007, an in vivo CAR-T program targeting systemic lupus erythematosus, and mRNA-2808 for multiple myeloma, currently in Phase 1/2 trials. The company also expects to initiate a Phase 1/2 trial for mRNA-4194 in Lynch syndrome this summer and release data for mRNA-1195 in multiple sclerosis in the second half of 2026.
Market Context and Risks
The broader market showed mixed signals on Friday, with the S&P 500 slipping 0.05% and the Nasdaq losing 0.24%, making Moderna's rally stand out among large-cap healthcare stocks. Early Monday, U.S. futures pointed higher, with S&P 500 E-minis up 0.68% and Nasdaq 100 E-minis up 1.02%.
Despite the recent gains, significant risks remain. The high short interest suggests that many traders expect a pullback, potentially triggered by the FDA decision or disappointing pipeline data. Moderna's current valuation of $26.69 billion market cap already reflects optimism about its pipeline, but near-term revenue catalysts are limited. The company has four approved products and anticipates possible launches in 2027 and 2028, including a flu-COVID combination shot and a norovirus vaccine.
As the August 5 FDA decision approaches, Moderna's stock faces a pivotal test. A positive outcome could validate the recent rally, while a setback might trigger a sharp reversal. Investors are advised to monitor the regulatory decision closely, as it will likely determine the stock's trajectory in the coming months.
